Addiction Medicine: Beyond the Abstract

In this episode, Dr. Jeanmarie Perrone sits down to discuss her new article The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine featured in the May/June issue of the Journal of Addiction Medicine. Jeanmarie Perrone, MD is a Professor in the Department of Emergency Medicine, the Director of Addiction Toxicology, and the founding Director of the Penn Center for Addiction Medicine and Policy, all at the University of Pennsylvania. Dr. Perrone has led multiple initiatives through the emergency department for the initiation of treatment for substance use disorders. Dr. Perrone has been recognized with several awards for education and mentorship and is board certified in emergency medicine, medical toxicology and addiction medicine. Article Link: The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine

In this episode, Dr. Vinit Patel sits down to discuss his new article Non-medical Mephentermine Use: A Systematic Review of Literature, as well as what exactly mephentermine is, why and how it is currently being used in non-medical settings specifically in India and South Asia, and some of the contributing factors associated with geographic disparities in non-medical mephentermine use. Article Link: Non-medical Mephentermine Use: A Systematic Review of Literature

Dr. Pouya Azar stops by the show to talk about his recent article Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative. He discusses the potential benefits of transitioning patients with opioid use disorder from traditional to extended-release or long-acting buprenorphine within 7 days or 24 hours, respectively, of treatment, as well as challenges and future questions that arose from his narrative review. Pouya Azar, MD, FRCPC, DABAM, is a clinician-scientist in addiction psychiatry and pain medicine based in Vancouver, British Columbia, Canada. He serves as co-medical manager of the Complex Pain and Addiction Service (CPAS) at Vancouver Coastal Health, a consult service providing management of pain, mental health disorders, and substance use disorders across Vancouver General Hospital, the University of British Columbia (UBC) Hospital, and GF Strong Rehabilitation Centre. He is also an assistant professor (tenure-track) in the UBC Department of Psychiatry, research scientist co-lead of the Substance Use Disorder Clinical Research Unit at the BC Centre for Excellence in HIV/AIDS, and a physician at the Vancouver General Hospital Transitional Pain Clinic. Dr. Azar’s clinical and translational research focuses on developing novel opioid agonist treatment initiation and withdrawal management protocols, medical devices, digital health apps, and prevention programs to improve patient outcomes. - Article Link: Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative

Dr. Emily Pasman stops by the show to talk about her recent article Nonabstinence Among US Adults in Recovery From an Alcohol or Other Drug Problem. She discusses the findings from her study as well as the potential limitations of using a solely abstinence-focused treatment and recovery model for addiction care. Emily Pasman is a licensed social worker and postdoctoral research fellow at the University of Michigan Center for the Study of Drugs, Alcohol, Smoking, and Health. Her research aims to improve health equity for people who use drugs by expanding harm reduction interventions; supporting affected family members; and addressing disparities in service access, uptake, and outcomes. Grounded in her practice background in peer-delivered services, she uses participatory methods to engage people with lived and living experience in all aspects of the research process. - Article Link: Nonabstinence Among US Adults in Recovery From an Alcohol or Other Drug Problem

In this episode, Regina LaBelle stops by to talk about her recent article featured in the Journal of Addiction Medicine titled, The First 100 Days: The Trump Administration and Changes to Addiction Policy. In this episode, Regina discusses structural, budgetary and personnel, and data collection changes that have occurred in the last 100 days and the potential impact on addiction policy. Regina LaBelle is the director of the Center on Addiction Policy at the O’Neill Institute for National and Global Health Law at Georgetown University Law Center. She is also a member of the faculty at Georgetown University’s Graduate School of Arts and Sciences, where she directs the Master of Science in Addiction Policy and Practice program, a program she founded in 2021. Regina has a history of public service, including in the Biden and Obama Administrations in the White House Office of National Drug Control Policy where she was appointed acting director in the first year of the Biden Administration. Under President Obama, Regina served as chief of staff at ONDCP where she managed the agency's response to the overdose epidemic and the implementation of the National Drug Control Strategy. She also serves on the National Advisory Council on Drug Abuse at the National Institutes of Health. - Article Link: The First 100 Days: The Trump Administration and Changes to Addiction Policy

In this episode, Dr. Charles Schauberger discusses the difficulties clinicians face when identifying and treating inhalant use in pregnant patients, and the findings from his recent article Systematic Review of Obstetric and Child Outcomes of Prenatal Exposure to Inhalants in the Context of a Use Disorder. Dr. Charles Schauberger lives and practices in La Crosse, Wisconsin. He is board-certified in both Obstetrics and Addiction Medicine, and has developed a specialized pregnancy addiction clinic that champions a patient-centered approach to addiction care for pregnant women. While he is mostly retired from obstetrics, he continues to provide addiction care and continues his interest in performing research studies to advance our knowledge of treatment for substances in pregnancy. - Article Link: Systematic Review of Obstetric and Child Outcomes of Prenatal Exposure to Inhalants in the Context of a Use Disorder